03:33 PM EST - Aeterna Zentaris Inc : and Hikma Pharmaceuticals PLC announced today the signing of an exclusive commercialization and licensing agreement for the registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for the MENA (Middle East and North Africa) region. Perifosine, a novel oral Akt inhibitor, is currently in two Phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. Aeterna Zentaris Inc
shares T.AEZ are trading up $0.06 at $1.73.
